An Information Portal to 110619 Biological Macromolecular Structures

1N1 is found in 13 entries
  •   Chemical Component Summary   Hide
    Identifiers N-(2-chloranyl-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
    Synonyms Dasatinib
    Formula C22 H26 Cl N7 O2 S
    Molecular Weight 488.01 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01254   (Stereoisomeric match)
    Name Dasatinib
    • approved
    • investigational
    Description Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
    • Anh. dasatinib
    • Anhydrous dasatinib
    • BMS dasatinib
    • BMS-354825
    • Dasatinib
    • Dasatinib (anh.)
    • Dasatinibum
    • N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
    Brand names Sprycel
    Affected organism Humans and other mammals
    Indication For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
    Pharmacology Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor
    Mechanism of action Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
    Route of administration oral
    ATC-Code L01XE06
    CAS number 302962-49-8
    Name Sequence search Pharmacological action Actions
    Tyrosine-protein kinase ABL1   Search  yes multitarget
    Platelet-derived growth factor receptor beta   Search  unknown antagonist
    Abelson tyrosine-protein kinase 2   Search  unknown multitarget
    Mast/stem cell growth factor receptor Kit   Search  unknown antagonist
    Proto-oncogene tyrosine-protein kinase Src   Search  yes multitarget
Ligand Image